Veradermics (NYSE:MANE) shares rose 9% on Wednesday after the company reported positive Phase 2 clinical data for VDPHL01, its investigational oral treatment for female pattern hair loss.
Phase 2 study delivers strong efficacy results
The company released findings from Study 207, an open-label Phase 2 trial evaluating its extended-release oral minoxidil formulation in women with mild-to-moderate pattern hair loss.
After six months of treatment, 88.9% of participants receiving the once-daily regimen and 90.0% of those taking the treatment twice daily reported that their condition had improved or was much improved.
Researchers also recorded a mean increase in non-vellus target area hair count of 22.7 hairs per square centimetre in the once-daily group and 23.3 hairs per square centimetre in the twice-daily group after six months of treatment.
Most participants began reporting noticeable improvements in hair coverage by Month 2, the earliest assessment point in the study.
Safety profile remains favourable
According to Veradermics, VDPHL01 demonstrated a favourable safety profile throughout the trial.
The company reported no treatment-related serious adverse events and no cardiac-related adverse events of special interest during the six-month study period.
Additional clinical milestones ahead
Veradermics expects topline data from Study 306, its Phase 2/3 trial evaluating VDPHL01 in female pattern hair loss, during the first half of 2027.
If successfully developed, the company believes VDPHL01 could become the first oral therapy approved by the U.S. Food and Drug Administration for female pattern hair loss.
The company is also advancing the treatment in male pattern hair loss.
Topline results from the Phase 3 Study 304 are expected in the second half of 2026, following the release of positive topline data from the registration-directed Phase 2/3 Study 302 announced earlier this year.
Veradermics stock price
